BioCentury
ARTICLE | Politics & Policy

MSKCC, ICER propose value-based pricing policies

December 1, 2015 3:11 AM UTC

In an Memorial Sloan Kettering Cancer Center's Peter Bach and Institute for Clinical and Economic Review President Steven Pearson proposed a set of policies private and public payers could adopt to promote the use of value-based drug pricing.

Bach and Pearson noted that in the U.S., the prescription drug sector is "the only major category of health care services for which the producer is able to exercise relatively unrestrained pricing power." New tools including MSKCC's Drug Abacus and ICER's value assessment reports are being developed to assess the value drugs provide, and other sectors of the healthcare system are moving towards value-based pricing, the authors noted. ...